Seattle—A shortage and then discontinuation of the third-generation cephalosporin cefotaxime may be leaving young infants at increased risk for infections and antibiotic resistance, according to research presented at the ACCP 2018 Global Conference on Clinical Pharmacy (poster MonAM-64).
That’s been the case at the University of Chicago Comer Children’s Hospital neonatal ICU, where the cefotaxime scarcity has complicated the management of sepsis and meningitis,